TrialSignal
Clinical trial intelligence report
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00089791
Status
COMPLETED
Phase
PHASE3
Sponsor
Amgen
Executive brief
Investment-Ready Snapshot
The FREEDOM trial evaluated the efficacy and safety of Denosumab, a monoclonal antibody, in reducing fractures in postmenopausal women with osteoporosis. Conducted by Amgen, the study enrolled 7,808 participants and demonstrated significant fracture risk reduction, positioning Denosumab as a competitive treatment option in the osteoporosis market.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00089791
Indication
Osteoporosis
Modality
monoclonal antibody
Target
Postmenopausal Osteoporosis
Intervention
placebo, Denosumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.